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Fig. 1. (A) Antimicrobial activity of Skl, LytA, and the 
chimeras against strain R6 of S. pneumoniae measured 
by following the decrease in OD550nm. (B) Viable cells 
after 60 min incubation. Measurements performed at 
37ºC, in PBS, pH 6.8, and 0.25 μg/ml of enzyme.
4. Conclusions
Systematic characterization of the Skl endolysin in 
comparison with the LytA autolysin has allowed 
to create a chimeric lysin, QSLA2, whose killing 
efficiency on S. pneumoniae exceeded to that of 
LytA.
Choline binding affinity and choline-promoted 
dimerization seems to be essential for the 
antipneumococcal activity of lysins with the same 
kind of CBM than LytA. Their alteration can be 
used as a tool to improve or modulate lysin activities. 
The differences found in the antimicrobial 
efficiencies of  LytA and QSLA2 denote the 
influence of  the CM and the overall modular 
architecture of lysins, another factor that could 
be used in the construction of enzybiotics with 
enhanced activities.
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ABSTRACT: 
The relentless increase in bacterial resistance to our current armamentarium of antibiotics could 
shortly take Europe and other global communities into a post-antibiotic era in which many common 
infections would be unable to be effectively treated. To avert this danger requires a fundamental change 
in antibacterial drug discovery that will involve the identification of new targets, the development of 
new chemical compounds. We present the MHit initiative, a Drug Discovery Platform that provides 
the framework for blending the academia innovative approaches together with their translation in 
real practical solutions, where the industry plays a fundamental role. 
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1. Introduction
The so-called “antibiotic era of drug discovery” 
(1920s-1960s) witnessed the appearance of  a 
number of molecular classes that constitute the 
basis of most of the antimicrobials in use today. 
However, discovery of fundamentally new classes 
of antibiotics came to an almost complete halt 
after the mid 1960s [1] despite the fact that the 
proportion of antibiotic resistant bacteria had 
been increasing over this period. Antimicrobial 
resistance causes profound problems with regard 
to infections due to Gram-positive microorganisms 
such as Staphylococcus aureus and Streptococcus 
pneumoniae (pneumococcus), which are among 
the most problematical bacterial pathogens 
worldwide. It is known that bacterial pneumonia is 
the major cause of childhood mortality worldwide 
along with malnutrition [2]. 
2. MHit Platform
The pharmaceutical industry has enjoyed a period 
of  immense success reaching a peak market 
capitalisation value and contributing real benefits 
to global healthcare. This notwithstanding, the 
industry today is facing some very real issues 
around its overall productivity [2,3]. 
Unquestionably, academia has a real atmosphere 
for creative and innovative science, assuming 
day-by-day research opportunities that are 
often ignored by the industry. Together with 
the innovative value of  the academia, the 
universities and public research institutes are 
today the reference for biomedical research with 
totally modernized infrastructures. Accordingly, 
potentiating research efforts in public research 
centres will notably contribute to increase the 
number of druggable target candidates [3,4]. 
XI European Meeting on the Molecular Biology of the Pneumococcus (EuroPneumo 2013)
Madrid, 28–31 May, 2013Madrid, 28–31 May, 2013
XI European Meeting on the Molecular Biology of the Pneumococcus (EuroPneumo 2013)
167166
MHit Platform is an academical initiative aimed 
in the identification of unexploited new bacterial 
targets that could provide the basis for the design 
and evaluation of  novel drugs. MHit owns a 
ChemioBank with target key metabolic steps 
in the biosynthesis of essential cellular building 
blocks of surface proteins or inhibit the function 
of virulence determinants necessary for bacterial 
pathogenesis. Small antimicrobial molecules have 
been identified from natural and synthetic sources 
and in vivo models for human diseases are fully 
operational within the consortium. From 2012, 
hit-to-lead process is guided under the most 
stringent regulatory basis to guarantee an efficient 
traslation to the productive sector. 
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ABSTRACT: 
The F1/F0 ATPase is the main proton pump of the aerotolerant anaerobic bacterium Streptococcus 
pneumoniae and is involved in building the proton gradient of the membrane, in the homeostasis 
of cations, the maintenance of the intracellular pH and influences the surface charge of the cell. 
We have isolated from murine blood a series of pneumococcal mutants with single nucleotide 
polymorphisms (SNP) in different subunits of the ATPase genes including strains with SNPs in 
atpA, atpB, atpC, atpD and atpG. Since these SNPs provided a selective advantage in the host over 
the challenge strain TIGR4, we performed a phenotypic analysis of these mutants. Upon the assays 
performed, in vivo NMR confirmed an unaltered intracellular pH, exposure to acid evidenced 
decreased acid survival, and zeta-potential and hydrophobicity tests revealed changes in surface 
charge. Phenotype microarray data for osmolites revealed that the challenge strain TIGR4 differed 
from reference strain D39 by decreased resistance to a series of compounds including sodium 
phosphate, sodium nitrate, sodium sulphate, sodium lactate, and ethylene glycol. Interestingly 
in four out five mutants assayed the resistance to osmolites had increased from the level of their 
parental strain TIGR4 to that of D39. While having important evidence for the fitness selection 
of a single virulent strain during experimental infection, these mutants are an exceptional tool 
to investigate into the physiological role of the essential F1/F0 ATPase enzyme complex of S. 
pneumoniae during infection of the host.
